Deuterated MK2 Pathway Inhibitors for Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune disorders, chronic inflammatory disorders, auto-inflammatory disorders, pain, atherosclerosis, diabetes, fibrotic diseases, metabolic disorders, cancer, neoplasia, leukemia, lymphoma, rheumatoid arthritis, and idiopathic pulmonary fibrosis are inadequate in efficacy and specificity.
Innovation Solution
Development of pharmaceutical compositions comprising compounds with the structure of Formula (I) and pharmaceutically acceptable excipients, which can be administered alone or in combination with other active compounds to treat these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for autoimmune and inflammatory disorders, then treatment coverage is provided, but efficacy and specificity are inadequate
Solution Approach 1:
The patent applies local quality by designing MK2 pathway inhibitors with specific molecular structures (Formula I) that target particular disease states. The compounds are designed with specific substituents (R1-R6 groups) that confer different selectivities for different autoimmune and inflammatory conditions, allowing each compound to be optimized for its specific therapeutic indication rather than using a one-size-fits-all approach.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the MK2 pathway inhibitors. The general Formula I structure allows for modification of substituents at multiple positions (R1-R6), enabling tuning of pharmacological properties such as potency, selectivity, and pharmacokinetic characteristics to address different disease mechanisms and patient populations.
2Stability of the object's composition
If deuterated compounds are synthesized, then metabolic stability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by incorporating deuterium atoms at specific positions in the molecular structure to enhance metabolic stability. The deuterium substitution at key metabolic vulnerability points modifies the compound's interaction with metabolic enzymes, extending half-life and reducing clearance without requiring complete redesign of the synthesis methodology.
Solution Approach 2:
The patent applies segmentation by introducing deuterium at specific, discrete positions within the molecular structure rather than throughout the entire molecule. This selective deuteration strategy focuses metabolic stability enhancement on critical sites while minimizing the complexity increase associated with synthesizing fully deuterated compounds.
Data Source
AI summary
The present disclosure provides deuterated pyridinone-pyridinyl compounds and compositions useful in the treatment of p38 MAP Kinase mediated having the structures of Formula (I); wherein the A, B, and R groups are as defined in the detailed description. Methods of inhibition of p38 MAP Kinase activity in a human or animal subject are also provided.